Remdesivir is indicated for treatment of COVID-19 in patients aged ≥ 12 years who weigh ≥ 40 kg (88.2 lb), have positive results on direct viral testing for SARS-CoV-2, and require hospitalization, or in those who are not hospitalized, have mild to moderate COVID-19, and are at high risk for progression to severe COVID-19 (including hospitalization or death).
Remdesivir, an antiviral agent, was the first treatment to gain full FDA approval for COVID-19. In addition to its approved indication, it has EUA for young children who weigh at least 3.5 kg as both inpatient and outpatient treatment regimens. It is administered by intravenous infusion.
Learn more about remdesivir indications.
Lead image: Pojoslaw | Dreamstime.com
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: COVID Treatments - Medscape - Mar 01, 2022.